Showing results (101-110 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|August 15, 2017
Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage studyRaúl U Hernández-Ramírez, Meredith S Shiels, Robert Dubrow, et al.
The Lancet. HIV|July 28, 2017
Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort studyJean-Michel Molina, Isabelle Charreau, Bruno Spire, et al.
The Lancet. HIV|August 4, 2017
Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysisRebecca F Baggaley, Michael A Irvine, Werner Leber, et al.
The Lancet. HIV|April 30, 2016
Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and UgandaRuanne V Barnabas, Heidi van Rooyen, Elioda Tumwesigye, et al.
The Lancet. HIV|November 19, 2017
Urgent versus post-stabilisation antiretroviral treatment in hospitalised HIV-infected children in Kenya (PUSH): a randomised controlled trialIrene N Njuguna, Lisa M Cranmer, Vincent O Otieno, et al.
The Lancet. HIV|November 28, 2017
Mortality and its determinants in antiretroviral treatment-naive HIV-infected children with suspected tuberculosis: an observational cohort studyOlivier Marcy, Mathurin Tejiokem, Philippe Msellati, et al.
The Lancet. HIV|November 26, 2020
Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept studyTheodore D Ruel, Edmund V Capparelli, Camlin Tierney, et al.
The Lancet. HIV|November 9, 2020
Community-based HIV testing services in an urban setting in western Kenya: a programme implementation studyHong-Ha M Truong, A Rain Mocello, David Ouma, et al.
The Lancet. HIV|December 24, 2022
Same-day initiation of oral pre-exposure prophylaxis among gay, bisexual, and other cisgender men who have sex with men and transgender women in Brazil, Mexico, and Peru (ImPrEP): a prospective, single-arm, open-label, multicentre implementation studyValdiléa G Veloso, Carlos F Cáceres, Brenda Hoagland, et al.
The Lancet. HIV|December 24, 2022
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trialSamir K Gupta, Mezgebe Berhe, Gordon Crofoot, et al.
Pageof 79